IFN-gamma and IL-10 are cytokine signaling molecules that play fundamental roles in inflammation, cancer growth and autoimmune diseases. Unfortunately, there are no specific inhibitors of IFN-gamma or IL-10 on the market to date. The National Cancer Institute seeks parties interested in licensing or collaborative research to co-develop selective IL-10 and IFN-gamma peptide inhibitors.
Researchers at the National Cancer Institute (NCI) RNA Biology Laboratory have developed nanoparticles that can deliver an agent (i.e., therapeutic or imaging) and release the agent upon targeted photoactivation allowing for controlled temporal and localized release of the agent.
Surgery specialists from Johns Hopkins University, in collaboration with researchers at the National Cancer Institute (NCI), developed peptide hydrogel compositions and methods to suture blood vessels during microsurgery. The hydrogels particularly benefit surgeons in whole tissue transplant procedures. The NCI seeks co-development research collaborations for further development of this technology.
Currently available topical antibiotic formulations effectively eliminate bacteria at a wound site. Eliminating bacteria in the wound also eliminates the molecular signals present in bacterial DNA that stimulate the immune system's wound healing processes. Without these signals, the rate of wound healing is diminished. The National Cancer Institute Laboratory of Experimental Immunology seeks parties interested in licensing a topical antibiotic formulation to accelerate wound healing.